Investors

Find comprehensive information about financial performance, corporate governance, and SEC filings.

SEC Filings

Stock Price

Board of Directors

Mark Wendland
+ Chairman of the Board
Mark Wendland was previously a Partner and Chief Operating Officer at DRW, a global trading firm with decades of experience across diverse markets and asset classes, including commodities, real estate, venture capital, and crypto assets. Mark joined DRW as its Global Head of Treasury in 2019. Previously he led U.S. Operations, Global Fixed Income Finance, Counterparty Strategy and Relationship Management at Citadel
Vincent LoPriore has served as a member of our board of directors since April 2025. Mr. LoPriore is an experienced financial professional with over 30 years of experience in the investment banking industry. He began his career at Oppenheimer & Co. in 1989 and subsequently held senior positions at Legg Mason, Inc. and partner at C.E. Unterberg, Towbin, where he led the special equities group and completed more than $150 million in private placement transactions. He has served in leadership roles at various boutique and mid-sized investment firms, focusing on capital raising, regulatory navigation. Mr. LoPriore is currently a Partner and licensed representative at President Street Global, LLC, a FINRA-registered broker-dealer. He also serves as the investment manager of the Gravitas Capital LP Fund, with a track record of strong investment performance. Mr. LoPriore has longstanding relationships within the biomedical industry and supports philanthropic initiatives including Race to Erase MS and Cure Addiction Now. Mr. LoPriore’s extensive investment banking experience and sector expertise support his qualifications to serve on the Board of Directors.
+ Independent Director
Gary Stetz has served as a member of our board of directors since April 2025. Mr. Stetz is a Certified Public Accountant with over 35 years of experience across accounting, finance, business valuation and corporate governance. Mr. Stetz currently serves as Managing Partner of Stetz, Belgiovine, Manwarren and Wallis P.C., an accounting, auditing, tax compliance and advisory services firm with more than 1,000 corporate clients. His extensive leadership experience includes founding Allegiance Community Bank and serving on the Board of BCB Bancorp. He is co-author of the book Project Management Accounting. He has earned multiple professional credentials, including Certified Mediator, Certified Fraud Examiner, and Chartered Global Management Accountant Mr. Stetz’s extensive expertise in financial forensics, valuation, and regulatory compliance will provide valuable oversight as Tharimmune continues to build a strong financial and operational foundation. Mr. Stetz’s extensive financial, accounting, and governance experience supports his qualifications to serve on the Board of Directors.
+ Independent Director
Clay Kahler has served as a member of our board of directors since April 2025. Mr. Kahler is a seasoned entrepreneur with decades of leadership experience in life sciences, biotechnology, and technology ventures. He is the Co-founder, CEO, and Managing Director of Spray Labs, LLC, an FDA-registered, cGMP-certified manufacturer specializing in oral spray drug delivery technologies. He is also the Founder and CEO of Gateway Sciences LLC, a company focused on regenerative medicine and mental health. Mr. Kahler co-founded Helius Medical Technologies, Inc. (NASDAQ: HSDT), where he played a pivotal role in structuring early corporate financing, facilitating the company’s public listing, and establishing strategic partnerships including worked with the team to secure a multi-million dollar Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense, through the U.S. Army Medical Research and Materiel Command (USAMRMC). These efforts helped propel the company to a peak market capitalization of approximately $500 million. He has also held multiple corporate advisory positions including UK-based Velocity Mobile Limited, doing business as Velocity Black, which was successfully acquired by Capital One Financial Corporation (NYSE: COF) in June 2023 for approximately $300 million. Mr. Kahler’s extensive leadership experience in public company operations, capital markets, and life sciences supports his qualifications to serve on the Board of Directors.
Sireesh Appajosyula currently is CEO of the Gravitas Life Sciences division.  He served as Tharimmune, Inc. CEO from June of 2025 to November 6, 2025 and joined as COO in July of 2023 while serving as a member of our board of directors since July 2021. Previously, he was SVP, Corporate Development and Operations of 9 Meters Biopharma, a company focused on rare and unmet needs and is Managing Member of Highpoint Pharmaceuticals, LLC, a pharmaceutical research and development company. Prior to 9 Meters, Dr. Appajosyula was at Salix Pharmaceuticals, Inc. (“Salix”) (Nasdaq: SLXP) in various roles in medical affairs, product commercialization and business development until its acquisition by Bausch Health (Nasdaq: BHC). Prior to Salix, he was involved in various roles at Amgen Inc., Critical Therapeutics, Inc. (now Chiesi) and Sanofi (formerly Aventis). Dr. Appajosyula received his Bachelor of Science and Doctor of Pharmacy from Rutgers University.
+ Independent Director
Jill Sommers has nearly three decades of experience in derivatives and financial markets, including serving two consecutive terms as a Commissioner of the U.S. Commodity Futures Trading Commission (“CFTC”). She most recently served as the Chair of the Derivative Practice Group of Potamak Global Partners until March 2025. Earlier in her career, Ms. Sommers held several senior policy and regulatory roles, including Policy Director and Head of Government Affairs at the International Swaps and Derivatives Association (“ISDA”) and Managing Director of Regulatory Affairs at the Chicago Mercantile Exchange.
+ Independent Director
William Wiley has deep capital markets experience as well as a track record leading complex global operations, including in his current role as Head of the Equities and Latency Sensitive Business Unit at DRW and Chief of Staff to DRW’s Founder and Chief Executive Officer. Mr. Wiley previously served as Chief Operating Officer of DRW’s Equities and Latency Sensitive Business Unit, overseeing day-to-day operations and scaling a global, multi-asset electronic trading platform. Prior to DRW, Mr. Wiley served as Global Head of Strategy at Instinet Holdings Inc. where he led firmwide strategy, operations, and strategic transactions across the institutional equities brokerage franchise.

Email Alerts